These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31751477)

  • 1. B-cell prolymphocytic leukemia has 3 subsets.
    Kay NE; Hanson CA
    Blood; 2019 Nov; 134(21):1777-1778. PubMed ID: 31751477
    [No Abstract]   [Full Text] [Related]  

  • 2. Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
    Eyre TA; Fox CP; Shankara P; Went R; Schuh AH
    Br J Haematol; 2017 May; 177(3):486-491. PubMed ID: 27061924
    [No Abstract]   [Full Text] [Related]  

  • 3. Aberrations of MYC are a common event in B-cell prolymphocytic leukemia.
    Flatley E; Chen AI; Zhao X; Jaffe ES; Dunlap JB; Pittaluga S; Abdullah S; Olson SB; Spurgeon SE; Fan G
    Am J Clin Pathol; 2014 Sep; 142(3):347-54. PubMed ID: 25125625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B- and T-cell prolymphocytic leukemia: antibody approaches.
    Dearden C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():645-51. PubMed ID: 23233647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
    Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
    Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation.
    Hoehn D; Miranda RN; Kanagal-Shamanna R; Lin P; Medeiros LJ
    Hum Pathol; 2012 Nov; 43(11):1828-38. PubMed ID: 22520947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
    Chapiro E; Pramil E; Diop M; Roos-Weil D; Dillard C; Gabillaud C; Maloum K; Settegrana C; Baseggio L; Lesesve JF; Yon M; Jondreville L; Lesty C; Davi F; Le Garff-Tavernier M; Droin N; Dessen P; Algrin C; Leblond V; Gabarre J; Bouzy S; Eclache V; Gaillard B; Callet-Bauchu E; Muller M; Lefebvre C; Nadal N; Ittel A; Struski S; Collonge-Rame MA; Quilichini B; Fert-Ferrer S; Auger N; Radford-Weiss I; Wagner L; Scheinost S; Zenz T; Susin SA; Bernard OA; Nguyen-Khac F; ;
    Blood; 2019 Nov; 134(21):1821-1831. PubMed ID: 31527074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auer Rod-Like Inclusions in B-Cell Prolymphocytic Leukemia.
    Zhao Y; Lv J
    Turk J Haematol; 2019 Nov; 36(4):280-281. PubMed ID: 30238921
    [No Abstract]   [Full Text] [Related]  

  • 9. Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
    Eyre TA; Fox CP; Boden A; Bloor A; Dungawalla M; Shankara P; Went R; Schuh AH
    Br J Haematol; 2019 Feb; 184(4):667-671. PubMed ID: 29468637
    [No Abstract]   [Full Text] [Related]  

  • 10. Auer Rod-Like Inclusions in Prolymphocytic Leukemia.
    Qiufan Z; Shumei X; Xifeng D; Shuwen D; Huaquan W; Zonghong S
    Clin Lab; 2015; 61(7):831-4. PubMed ID: 26299084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Damlaj M; Al Balwi M; Al Mugairi AM
    Leuk Lymphoma; 2018 Mar; 59(3):739-742. PubMed ID: 28695755
    [No Abstract]   [Full Text] [Related]  

  • 12. B-cell prolymphocytic leukemia after COVID-19 infection.
    Falini B; Lazzi S
    Blood; 2023 Apr; 141(14):1777. PubMed ID: 37022732
    [No Abstract]   [Full Text] [Related]  

  • 13. B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.
    Del Giudice I; Osuji N; Dexter T; Brito-Babapulle V; Parry-Jones N; Chiaretti S; Messina M; Morgan G; Catovsky D; Matutes E
    Leukemia; 2009 Nov; 23(11):2160-7. PubMed ID: 19641528
    [No Abstract]   [Full Text] [Related]  

  • 14. Retrospective analysis of a cohort of 41
    Algrin C; Pérol L; Chapiro E; Baseggio L; Maloum K; Settegrana C; Lesesve JF; Siavellis J; Delmer A; Michallet AS; Ferrant E; Feugier P; Tomowiak C; Brion A; Ghez D; Fornecker LM; Ivanoff S; Struski S; Sutton L; Radford-Weiss I; Eclache V; Lefebvre C; Leblond V; Nguyen-Khac F; Roos-Weil D
    Haematologica; 2023 Jun; 108(6):1691-1696. PubMed ID: 36546425
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytogenetic studies in chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia: a progress report.
    Han T; Sadamori N; Block AM; Xiao H; Henderson ES; Emrich L; Sandberg AA
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):393-5. PubMed ID: 3222149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent chronic lymphocytic leukemia and prolymphocytic leukemia derived from two separate B-cell clones.
    Cao F; Amato D; Wang C
    Am J Hematol; 2011 Sep; 86(9):782. PubMed ID: 21465516
    [No Abstract]   [Full Text] [Related]  

  • 18. [Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].
    Telek B; Batár P; Rejto L; Udvardy M
    Orv Hetil; 2010 Aug; 151(31):1261-3. PubMed ID: 20656663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CD5-positive B-cell prolymphocytic leukemia].
    Inoue T; Yoshida M; Oowashi K; Yoshida T
    Rinsho Ketsueki; 2010 Jan; 51(1):80-2. PubMed ID: 20134145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.
    Moore J; Baran AM; Meacham PJ; Evans AG; Barr PM; Zent CS
    Am J Hematol; 2020 May; 95(5):E108-E110. PubMed ID: 31951033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.